Aspect Biosystems and Novo Nordisk recently announced a collaboration, development, and licence agreement to develop bioprinted tissue therapeutics designed to replace, repair, or supplement biological functions inside the body with the aim of delivering a new class of truly disease-modifying treatments for diabetes and obesity. The collaboration will leverage Aspect’s proprietary bioprinting technology and Novo Nordisk’s expertise and technology in stem cell differentiation and cell therapy development and manufacturing.
Aspect Biosystems presented at the OBIO® Investment Summit and Novo Nordisk participated at the inaugural Pharma Licensing Forum at the 2023 OBIO® Investment Summit.